Sutro Biopharma (NASDAQ:STRO – Get Free Report) is expected to issue its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Sutro Biopharma to post earnings of ($2.2204) per share and revenue of $11.7760 million for the quarter. On average, analysts expect Sutro Biopharma to post $-9 EPS for the current fiscal year and $-7 EPS for the next fiscal year. Get Sutro Biopharma alerts:Sutro Biopharma Price PerformanceNASDAQ:STRO traded up $0.37 during mid-day trading on Tuesday, reaching $25.47. See AlsoReceive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.